CoChat

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition

Open access
Young, Helen L., Rowling, Emily J., Bugatti, Mattia, Giurisato, Emanuele, Luheshi, Nadia, Arozarena, Imanol, Acosta, Juan-Carlos, Kamarashev, Jivko, Frederick, Dennie T., Cooper, Zachary A., Reuben, Alexandre, Gil, Jesus, Flaherty, Keith T., Wargo, Jennifer A., Vermi, William, Smith, Michael P., Wellbrock, Claudia, Hurlstone, Adam · 2017 · Journal of Experimental Medicine
Cited by 95

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Mitogen-activated protein kinase (MAPK) pathway antagonists induce profound clinical responses in advanced cutaneous melanoma, but complete remissions are frustrated by the development of acquired resistance. Before resistance emerges, adaptive responses establish a mutation-independent drug tolerance. Antagonizing these adaptive responses could improve drug effects, thereby thwarting the emergence of acquired resistance. In this study, we reveal that inflammatory niches consisting of tumor-associated macrophages and fibroblasts contribute to treatment tolerance through a cytokine-signaling network that involves macrophage-derived IL-1β and fibroblast-derived CXCR2 ligands. Fibroblasts require IL-1β to produce CXCR2 ligands, and loss of host IL-1R signaling in vivo reduces melanoma growth. In tumors from patients on treatment, signaling from inflammatory niches is amplified in the presence of MAPK inhibitors. Signaling from inflammatory niches counteracts combined BRAF/MEK (MAPK/extracellular signal–regulated kinase kinase) inhibitor treatment, and consequently, inhibiting IL-1R or CXCR2 signaling in vivo enhanced the efficacy of MAPK inhibitors. We conclude that melanoma inflammatory niches adapt to and confer drug tolerance toward BRAF and MEK inhibitors early during treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20160855

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 95

Metadata

Authors
Young, H. L., Rowling, E. J., Bugatti, M., Giurisato, E., Luheshi, N., Arozarena, I., Acosta, J.-C., Kamarashev, J., Frederick, D. T., Cooper, Z. A., Reuben, A., Gil, J., Flaherty, K. T., Wargo, J. A., Vermi, W., Smith, M. P., Wellbrock, C., & Hurlstone, A.
Venue
Journal of Experimental Medicine
Published
2017-04-27
Volume
214
Issue
6
Pages
1691-1710
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2606673077
Cited by
95
References
15
FWCI
3.98
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. https://app.cochat.ai/papers/10.1084/jem.20160855
The paper
Young, H. L., Rowling, E. J., Bugatti, M., Giurisato, E., Luheshi, N., Arozarena, I., Acosta, J.-C., Kamarashev, J., Frederick, D. T., Cooper, Z. A., Reuben, A., Gil, J., Flaherty, K. T., Wargo, J. A., Vermi, W., Smith, M. P., Wellbrock, C., & Hurlstone, A. (2017). An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20160855

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.